References
- Disease management consensus statement. New York, NY: National Multiple Sclerosis Society. Available from http://www. nationalmssociety.org/Sourcebook-Early.asp [Last accessed 28 Nov 2006]
- Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis. Review of adverse effect profiles. CNS Drugs 2005;19:1–14
- IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655–61
- Jacobs LD, Cookfair DL, Rudick RA, et al., and the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–94
- PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504
- Mohr DC, Likosky W, Boudewyn AC, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998;4:487–9
- Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the β-interferons prescribed for MS. Neurology 2003;61: 551–4
- O’Rourke KET, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46–50
- Rio J, Nos C, Marzo ME, et al. Low-dose steroids reduce flu-like symptoms at the initiation of IFNβ-1b in relapsing-remitting MS. Neurology 1998;50:1910–2
- Reess J, Haas J, Gabriel K, et al. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsingremitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy. Mult Scler 2002;8:15–8
- Río J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNβ-1a flu symptoms in MS. A randomized trial. Neurology 2004;63: 525–8
- Rice GPA, Ebers GC, Lublin FD, et al. Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS. Neurology 1999;52:1893–5
- Wroe SJ. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 2005;33:309–18
- Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227–36